The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) today announced that it has been awarded a $1.4 million grant from the Food & Drug Administration (FDA) to enable biosimilar research.
Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.
Due to the COVID-19 PHE, flexibilities were implemented to prevent lapses in
patient care by allowing the prescribing of schedule II-V controlled medications via
audio-video telemedicine encounters – including schedule III-V narcotic controlled
medications approved by the Food and Drug Administration (FDA) for
maintenance and withdrawal management of opioid use disorder – even when the
prescribing practitioner had not conducted an in-person medical evaluation of the
patient.
Host Fred Goldstein discusses current biologic options and the impact to the Immunology Market landscape with Michael Rothrock MHA, MBA, and Chronis H. Manolis, RPh.
Due to the COVID-19 PHE, flexibilities were implemented to prevent lapses in
patient care by allowing the prescribing of schedule II-V controlled medications via
audio-video telemedicine encounters – including schedule III-V narcotic controlled
medications approved by the Food and Drug Administration (FDA) for
maintenance and withdrawal management of opioid use disorder – even when the
prescribing practitioner had not conducted an in-person medical evaluation of the
patient.
On August 29, the Centers for Medicare & Medicaid Services (CMS) announced
the first 10 Part D drugs selected for negotiation under the Medicare Drug Price
Negotiation Program. The negotiation process for these drugs will take place
during 2023 and 2024, and maximum fair prices will be applicable starting in 2026.
Health care expert Fred Goldstein sits down with Adam Colborn, director of government affairs at AMCP, to discuss AMCP’s federal policy priorities in the 118th Congress.
In her latest blog, AMCP CEO Susan Cantrell recaps our inaugural workshop on the IRA, reinforcing that there is still a great deal of uncertainty as key milestones approach. Learn how AMCP is addressing concerns this landmark legislation is causing across managed care pharmacy and the larger healthcare industry.
